TSX/HBP (TSX/HBP)

Toronto Stock Exchange: TSX/HBP · CAD

CA$0.99

+0.00 (0.0%)· Recorded snapshot

Market cap	75.6M
Net income (ttm)	-3.3M
EPS (ttm)	-CA$0.04
Shares out	76.4M
Volume	0
Beta	-0.14

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -3.3M
EPS (ttm): -CA$0.04
Market cap: 75.6M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 11P50 16.8P75 23.9

Trailing P/En/a

P25 9.9P50 23.3P75 38.5

ROE-50

P25 -104.1P50 -30P75 6.7

ROIC-29.8

P25 -55.9P50 -12.1P75 5

Benchmarks · 1M

All TSX/HBP indicators

Market & fundamental data

Available fields

158

Groups with data

Currency

CAD

Showing 158 of 158 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	CAD
Country	Canada
Country code	CA
Earnings date	2026-11-04
Employees	7
Employees change	-2
Employees growth	-22.22%
Enterprise value	CAD 73.1M
Exchange	Toronto Stock Exchange
Financial currency	CAD
Financial report date	2026-04-30
First seen	2026-05-10
Fiscal year end	July
Founded	2008
Industry	Biotechnology
Is primary listing	Yes
ISIN number	CA4229102088
Last earnings date	2025-12-12
Last refreshed	2026-10-29
Last stock split date	2024-08-16
Last stock split type	Reverse
Market cap	CAD 75.6M
Next earnings date	2026-11-04
Price	CAD 0.99
Price currency	CAD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	tsx/HBP
Website	https://www.helixbiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4.48%
FCF / EV yield	-4.36%
FCF yield	-4.22%
P/B ratio	5.15x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	CAD -474,857
ROA	-18.19%
ROA (5Y)	-176.42%
ROCE	-22.19%
ROE	-49.99%
ROIC	-29.82%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	1
Net income growth quarters	5
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	CAD 0
Depreciation and amortization	CAD 4,000
EBIT	CAD -3.3M
EBITDA	CAD -3.3M
EPS	CAD -0.04
FCF per share	CAD -0.04
Financing cash flow	CAD 5.3M
Free cash flow	CAD -3.2M
Free cash flow minus SBC	CAD -3.2M
Net cash flow	CAD 2.1M
Net income	CAD -3.3M
Operating cash flow minus SBC	CAD -3.2M
Operating income	CAD -3.3M
Stock-based compensation	CAD 22,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	CAD 0.19
Debt / equity	0.02
Interest coverage	-90.53
Long-term assets	CAD 18.4M
Long-term liabilities	CAD 0
Net cash (debt)	CAD 2.5M
Net cash / market cap	3.28%
Net cash growth	247.13%
Net debt / equity	-0.17
Piotroski F-Score	2
Property, plant and equipment	CAD 1,000
Shareholders' equity	CAD 14.7M
Tangible book value	CAD -3.7M
Tangible book value per share	CAD -0.05
Total assets	CAD 21.4M
Total cash	CAD 2.8M
Total debt	CAD 360,000
Total liabilities	CAD 6.7M
WACC	3.51%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	CAD 3M
Current liabilities	CAD 6.7M
Current ratio	0.45
Net working capital	CAD -6.2M
Quick ratio	0.43
Working capital	CAD -3.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-46.69%
Shareholder yield	-46.69%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-87.23%
10Y return CAGR	-18.6%
10Y total return	-87.23%
150-day SMA	CAD 1.59
15Y price change	-90.57%
15Y return CAGR	-14.57%
15Y total return	-90.57%
1D price change	0%
1M price change	-3.88%
1M total return	-3.88%
1W price change	1.02%
1W total return	1.02%
1Y price change	-53.52%
1Y return CAGR	-53.55%
1Y total return	-53.52%
20-day SMA	CAD 0.97
200-day SMA	CAD 1.73
20Y price change	-89.85%
20Y return CAGR	-10.81%
20Y total return	-89.85%
3M price change	-31.25%
3M total return	-31.25%
3Y price change	-1%
3Y return CAGR	-0.33%
3Y total return	-1%
50-day SMA	CAD 1.42
50-day SMA vs 200-day SMA	50under200
52-week high	CAD 2.60
52-week high date	2025-11-17
52-week low	CAD 0.82
52-week low date	2026-10-23
5Y price change	-63.33%
5Y return CAGR	-18.18%
5Y total return	-63.33%
6M price change	-47.62%
6M total return	-47.62%
All-time high	CAD 40.25
All-time high date	2000-10-10
All-time low	CAD 0.50
All-time low date	2024-11-06
Average true range (ATR)	CAD 0.11
Average volume	15.6K
Beta (1Y)	1.61
Beta (2Y)	2.62
Beta (5Y)	-0.14
Change from 52-week high	-61.92%
Change from 52-week low	20.73%
Change from all-time high	-97.54%
Change from all-time low	98%
Monthly RSI	41.92
Previous close	CAD 0.99
Price vs 150-day SMA	-37.66%
Price vs 20-day SMA	1.64%
Price vs 200-day SMA	-42.84%
Price vs 50-day SMA	-30.43%
Relative volume	0.01
RSI	43.32
Sharpe ratio	0.13
Sharpe ratio (3Y)	0.48
Sharpe ratio (5Y)	0.29
Sortino ratio	0.26
Sortino ratio (3Y)	0.81
Sortino ratio (5Y)	0.51
Volume	0
Weekly RSI	36.73
YTD price change	-58.23%
YTD total return	-58.23%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	46.7M
Shares change (QoQ)	0%
Shares change (YoY)	46.69%
Shares held by insiders	11.33%
Shares outstanding	76.4M

Deeper analysis on TSX/HBP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TSX/HBP report

Is a complete TSX/HBP research report available?

No complete published report is available for tsx/HBP (TSX/HBP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

TSX/HBP (TSX/HBP)

Price

Financial snapshot

Fair-value bridge

Latest news · TSX/HBP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TSX/HBP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TSX/HBP

Frequently asked questions